Skip to main content

Advertisement

Table 1 Demographic and pre-treatment data according to the treatments employed

From: Neurological outcome of treatment for patients with impending paralysis due to epidural spinal cord compression by metastatic spinal tumor

Type of treatment Posterior stabilization with decompression (n = 18) Posterior stabilization without decompression (n = 15) Radiotherapy (n = 55)
Male vs. female 12:6 9:6 40:15
Age (years), mean 39–83, 62.5 ± 11.8 40–82, 63.1 ± 13.9 36–85, 65.5 ± 11.5
The level of the spine that exhibited the greatest tumor-related spinal cord compression
 C1-T2 level 5 3 9
 T3-L1 level 6 4 22
 L2-S1 level 7 8 24
No. of affected vertebral body, mean 1–4, 2.1 ± 1.1 1–12, 3.5 ± 3.4 1–9, 3.3 ± 2.2
Primary site
 Lung 6 5 31
 Kidney 3 1 2
 Prostate 1 1 4
 Liver 3 3 6
 Breast 1 3 0
 Others 4 2 12
No. of VAS 0 0 (0%) 0 (0%) 6 (10.9%)
Transverse location
 A 3 5 23
 AP 2 2 15
 AF 9 6 6
 APF 4 2 11
ESCC scale
 1b 9 7 28
 1c 5 5 19
 2 2 3 7
 3 2 0 1
Spinal instability neoplastic score 10.1 ± 2.4 10.5 ± 2.5 9.3 ± 2.4
Additional adjuvant therapy Radiotherapy 8, chemotherapy 11, BMA 3, no 2 Radiotherapy 11, chemotherapy 9, BMA 2, no. 1 Chemotherapy 20, BMA 17, no. 17
Survival period (months), mean 1–116, 16.0 ± 28.0 2–14, 7.2 ± 3.9 0.3–34, 7.7 ± 7.5
Pre-treatment Barthel index, mean 49–100, 81.5 ± 20.7 70–85, 77.5 ± 10.6 10–100, 68.0 ± 30.6
  1. VAS visual analog scale score, A anterior lesion, AP anterior + posterior lesion, AF anterior + foraminal lesion, APF anterior + posterior + foraminal lesion, ESCC epidural spinal cord compression, BMA bone-modifying agent